This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation | MicrobiomeTrials
← Back to trials NCT05790213
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-05-05Est. Completion: 2028-12-18
Enrollment target: 57 participantsLocations UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States Other microbiome trials you might be interested in PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK)…
El Paso, United States Est. completion Jul 10, 2028
Prostate Cancer (Post Prostatectomy) Radiotherapy; Image-Guided Prostate Cancer Non-Metastatic Androgen Deprivation Therapy Lymph Node Positive
The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation thera…
Dongguan, China Est. completion Dec 31, 2033